Armed with $12 million in series A cash, Emulate Inc. is developing organs-on-chips to more rapidly and reliably predict human response to medicine than traditional animal models.

Last week, Emulate spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University and announced the round, which was led by NanoDimension. Cedars-Sinai Medical Center and Hansjorg Wyss, the founder of the Wyss Institute, also participated.